Trial · NCT07905989
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Side effect 2 Number of patients with Headache | 12 weeks | Number of patients with Headache |
| Primary | Side effect 1 Number of patients with fatigue | 12 weeks | Number of patients with fatigue |
| Primary | Side effect 3 Number of patients with nausea | 12 weeks | Number of patients with nausea |
| Primary | Side effect 4 Number of patients with diarrhea | 12 weeks | Number of patients with diarrhea |
| Primary | Side effect 5 Number of patients with insomnia | 12 weeks | Number of patients with insomnia |
| Primary | Side effect 6 Number of patients with weakness | 12 weeks | Number of patients with weakness |
| Primary | Side effect 7 Number of patients with bradycardia | 12 weeks | Number of patients with bradycardia |
| Primary | Side effect 8 Number of patients with cough | 12 weeks | Number of patients with cough |
| Primary | Side effect 9 Number of patients with myalgia | 12 weeks | Number of patients with myalgia |
| Primary | Side effect 10 Number of patients with dyspnea | 12 weeks | Number of patients with dyspnea |
| Primary | Side effect 11 Number of patients with irritability | 12 weeks | Number of patients with irritability |
| Primary | Side effect 12 Number of patients with dizziness | 12 weeks | Number of patients with dizziness |
| Primary | Side effect 13 Number of patients with depression | 12 weeks | Number of patients with depression |
| Primary | Side effect 14 Number of patients with skin rash | 12 weeks | Number of patients with skin rash |
| Secondary | HCV-RNA PCR by the end of therapy | 12 weeks | HCV-RNA PCR at week 12 |
| Secondary | HCV-RNA PCR after 20 weeks for SVR | 20 weeks | HCV-RNA PCR at week 20 |
| Other | Treatment safety-1 Alanine transaminase serum level | 12 weeks | Alanine transaminase serum level |
| Other | Treatment safety-2 Aspartate transaminase serum level | 12 weeks | Aspartate transaminase serum level |
| Other | Treatment tolerability- 1 Patient height | 20 weeks | measurement of height |
| Other | Treatment tolerability-2 Body weight | 20 weeks | measurement of weight |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07905989/registered